Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMT 260

Drug Profile

AMT 260

Alternative Names: AAV9-hSyn1-miGRIK2; AMT-260

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corlieve Therapeutics
  • Developer Corlieve Therapeutics; uniQure
  • Class Antiepileptic drugs; Gene therapies; MicroRNAs
  • Mechanism of Action Kainic acid receptor antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Temporal-lobe-epilepsy

Most Recent Events

  • 07 May 2024 uniQure plans a phase I/IIa trial in Temporal lobe epilepsy (Treatment-experienced) in USA in the third quarter of 2024
  • 28 Feb 2024 UniQure has patents pending entitled "Methods and compositions for treating epilepsy" in Israel, Australia and Canada
  • 17 Nov 2023 Phase-I/II clinical trials in Temporal lobe epilepsy in USA (Intracerebral) (NCT06063850)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top